CN101035535A - 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途 - Google Patents

4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途 Download PDF

Info

Publication number
CN101035535A
CN101035535A CNA2005800338341A CN200580033834A CN101035535A CN 101035535 A CN101035535 A CN 101035535A CN A2005800338341 A CNA2005800338341 A CN A2005800338341A CN 200580033834 A CN200580033834 A CN 200580033834A CN 101035535 A CN101035535 A CN 101035535A
Authority
CN
China
Prior art keywords
fms
compound
csf
methyl
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800338341A
Other languages
English (en)
Chinese (zh)
Inventor
A·L·迪尤尔
T·P·休斯
A·B·里昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of CN101035535A publication Critical patent/CN101035535A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800338341A 2004-10-18 2005-10-17 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途 Pending CN101035535A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
US60/619,744 2004-10-18

Publications (1)

Publication Number Publication Date
CN101035535A true CN101035535A (zh) 2007-09-12

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800338341A Pending CN101035535A (zh) 2004-10-18 2005-10-17 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途

Country Status (19)

Country Link
US (1) US20080255139A1 (https=)
EP (1) EP1804800B1 (https=)
JP (1) JP2008516898A (https=)
KR (1) KR20070083705A (https=)
CN (1) CN101035535A (https=)
AT (1) ATE492277T1 (https=)
AU (1) AU2005297321A1 (https=)
BR (1) BRPI0517083A (https=)
CA (1) CA2580976A1 (https=)
DE (1) DE602005025514D1 (https=)
IL (1) IL182419A0 (https=)
MA (1) MA28946B1 (https=)
MX (1) MX2007004660A (https=)
NO (1) NO20072501L (https=)
NZ (1) NZ554009A (https=)
RU (1) RU2007118420A (https=)
TN (1) TNSN07141A1 (https=)
WO (1) WO2006042362A1 (https=)
ZA (1) ZA200702316B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058968A2 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
CN107530430A (zh) * 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt

Also Published As

Publication number Publication date
AU2005297321A1 (en) 2006-04-27
MA28946B1 (fr) 2007-10-01
DE602005025514D1 (de) 2011-02-03
NO20072501L (no) 2007-05-15
KR20070083705A (ko) 2007-08-24
NZ554009A (en) 2010-09-30
JP2008516898A (ja) 2008-05-22
IL182419A0 (en) 2007-09-20
TNSN07141A1 (en) 2008-11-21
EP1804800B1 (en) 2010-12-22
ZA200702316B (en) 2008-09-25
WO2006042362A1 (en) 2006-04-27
CA2580976A1 (en) 2006-04-27
EP1804800A4 (en) 2008-03-19
BRPI0517083A (pt) 2008-09-30
ATE492277T1 (de) 2011-01-15
EP1804800A1 (en) 2007-07-11
RU2007118420A (ru) 2008-11-27
MX2007004660A (es) 2007-10-17
US20080255139A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
CA3065365C (en) USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
US10314834B2 (en) Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
KR20150054962A (ko) 국소 진행성 유방암의 치료방법
US12516024B2 (en) KDM4 inhibitors
TW201522632A (zh) 弗林蛋白酶（ｆｕｒｉｎ）基因抑制及ｇｍ-ｃｓｆ增強（ｆａｎｇ）之癌症疫苗
JP5576290B2 (ja) 白血病の管理における３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体の用途
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
Orlen et al. T-cell dependency of tumor regressions and complete responses with RAS (ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma
CN1921864A (zh) 使用TGF－β抑制剂治疗神经胶质瘤
CN101146549A (zh) 抗血管新生剂与阿地白介素
EA028062B1 (ru) Лечение рака ингибиторами tor киназы
RU2630975C2 (ru) Режим дозирования pi-3 киназы
JP2014532658A (ja) ブルトン型チロシンキナーゼ疾患または障害を治療する方法
TWI741286B (zh) 治療癌症之方法
CN114246864B (zh) Csf1r激酶抑制剂及其用途
JP2021536507A (ja) Ｈｅｒ駆動性がんを治療または予防するための化合物、組成物、及び方法
US20160303137A1 (en) Dual pi3k and wnt pathway inhibition as a treatment for cancer
Diaz-Flores et al. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras
JP2017500369A (ja) ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
JP2021535198A (ja) 膵臓癌を治療する方法
CN1874776A (zh) 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈
CN101035535A (zh) 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途
WO2025157287A1 (zh) 包含prmt5抑制剂和egfr抑制剂的药物组合物
JP2024514958A (ja) ユビキチン特異的ペプチダーゼ２２（ｕｓｐ２２）の阻害剤、並びに疾患及び障害の治療のためのその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20070912

C20 Patent right or utility model deemed to be abandoned or is abandoned